

Appendix A

Search Terms:

'(((coronavirus or corona-virus) AND (wuhan or beijing or shanghai or Italy or South-Korea or korea or China or Chinese or 2019-nCoV or nCoV or COVID-19 or Covid19 or SARS-CoV* or SARSCov2 or ncov)) OR (pneumonia AND Wuhan) or "COVID-19" or "2019-nCoV" or "SARS-CoV" or SARSCOV2 or 2019-nCov or "2019 coronavirus" or "2019 corona virus" or covid19 or ncov OR "novel corona virus" or "new corona virus" or "nouveau corona virus" or "2019 corona virus" OR "novel coronavirus" or "new coronavirus" or "nouveau coronavirus" or "2019 coronavirus" or "Long Covid") NOT Animal:DB'

Appendix B

Data Extraction

Table 1. Data extraction template for identifying duplicate reviews

Record number	Research area	Date submitted	Date registered	Is the PICOS similar/identical to existing review?	Answer to screening question? *	Is the review funded?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there a reason for duplication from our perspective?

*Screening questions before authors submit a PROSPERO registration ask whether their review is not similar to an existing review, sufficiently different, or similar to an existing review, but repetition is needed

Appendix C

COVID-19 Systematic Review Duplication in PROSPERO Questionnaire

The survey can be entirely anonymous. But it would be useful for us to be able to link your responses to the PROSPERO record, so you can choose to include your personal information. If you do provide your identifying ID number, this will not be included or used in any future publications and it will not affect the status of your PROSPERO registration.

This survey has been granted ethical approval. If you choose to include your PROSPERO registration number, your data will be handled in compliance with GDPR and the UK Data Protection Act (2018). For more information, please visit the links on the University of York's policy on [Data Protection Legislation](#), [GDPR compliant research](#) and the [general privacy notice](#).

Q1 What is your PROSPERO registration number

About your COVID-19 related systematic review

Q2 Have you conducted a systematic review before?

- Yes (1)
- No (2)
- Other (3) _____

Q3 What research area was your systematic review looking at?

- Epidemiology (1)
- Transmission (2)
- Treatments (3)
- Other (4) _____

Q4 Why did you conduct your systematic review on a COVID-19 related topic?

- To inform future research that you had planned (such as a primary research study) (1)
- To inform funders/policy makers (2)
- For personal/departmental interest (3)
- Other (4) _____

Q5 Please provide details of the country in which the review is being carried out. For multi-national collaborations, give details of all the countries involved.

Q6 Is your review funded

- Yes (1)
- No (2)
- Other (3) _____

Display This Question:

If Is your review funded != No

Q7 If your review is funded, please provide details of the individuals, organizations, groups or other legal entities who take responsibility for initiating, managing, sponsoring and/or financing the review

Q8 Do you intend to publish or disseminate the results of your systematic review?

- Yes (1)
- No (2)
- Maybe (3)
- Other (4) _____

Display This Question:

If Do you intend to publish or disseminate the results of your systematic review? = No

Q9 Why did you decide not to publish the results of your systematic review?

Q10 Is there any other information that you wish to provide about your systematic review?

The following questions were specific to the registrant's response to the triage questions at PROSPERO submission

Not Similar Sub-Questions

When registering, users are prompted to search PROSPERO and check whether a similar systematic review has been registered. Some duplication, intended with good reason (e.g. the existing one is out of date or used suboptimal methods), is justifiable. When registering, you indicated that your review was not similar to an existing review

Q12 To help us understand this further, please indicate which statement applies most to your situation.

- I searched PROSPERO prior to registration and identified some/all of the similar records (1)
- I searched PROSPERO prior to registration but did not identify the similar records (2)
- I did not search PROSPERO prior to registration (3)

Display This Question:

If To help us understand this further, please indicate which statement applies most to your situation. = I searched PROSPERO prior to registration and identified some/all of the similar records

Q13 Please could you tell us more about the reasons you conducted a review similar to those which you identified?

Display This Question:

If To help us understand this further, please indicate which statement applies most to your situation. = I searched PROSPERO prior to registration but did not identify the similar records

Q14 Please could you tell us more about how you searched PROSPERO, including the search terms you used. This could help us to improve our guidance about how to search PROSPERO in the future.

Display This Question:

If To help us understand this further, please indicate which statement applies most to your situation. = I did not search PROSPERO prior to registration

Q15 Please could you tell us more about the reasons you did not search PROSPERO before registration?

Sufficiently Different Sub-Questions

When registering, users are prompted to search PROSPERO and check whether a similar systematic review has been registered. Some duplication, intended with good reason (e.g. the existing one is out of date or used suboptimal methods), is justifiable. When registering, you indicated that your review was similar to an existing review but sufficiently different to justify this review.

Q12 To help us understand this further, please indicate which statement applies most to your situation.

- I searched PROSPERO and identified some/ all of the existing reviews that were similar to my own. (1)
- Other (2)

Display This Question:

If To help us understand this further, please indicate which statement applies most to your situation. = I searched PROSPERO and identified some/ all of the existing reviews that were similar to my own.

Q13 For each of the similar reviews you identified, please could you tell us more about the reasons why your review is sufficiently different.

Display This Question:

If To help us understand this further, please indicate which statement applies most to your situation. = Other

Q14 Please could you tell us whether you searched PROSPERO, and if you did, please could you explain more about how you searched PROSPERO, including the search terms you used. This could help us to improve our guidance about how to search PROSPERO in the future.

Repetition Needed Sub-Questions

When registering, users are prompted to search PROSPERO and check whether a similar systematic review has been registered. Some duplication, intended with good reason (e.g. the existing one is out of date or used suboptimal methods), is justifiable. When registering, you indicated that your review was similar to an existing review but repetition was needed.

Q12 To help us understand this further, please indicate which statement applies most to your situation.

- I searched PROSPERO and identified some/ all of the existing reviews that were similar to my own. (1)
- Other (2)

Display This Question:

If To help us understand this further, please indicate which statement applies most to your situation. = I searched PROSPERO and identified some/ all of the existing reviews that were similar to my own.

Q13 For each of the similar reviews you identified, please could you tell us more about the reasons why repetition was needed.

Display This Question:

If To help us understand this further, please indicate which statement applies most to your situation. = Other

Q14 Please could you tell us whether you searched PROSPERO, and if you did, please could you explain more about how you searched PROSPERO, including the search terms you used. This could help us to improve our guidance about how to search PROSPERO in the future.

Appendix D

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Cancer	17/04/20	21/04/20	-	-	-	-	None
Cancer	22/04/20	22/04/20	NS	No	No	Perhaps, submitted one day after last was published	None
Cardiovascular Disease	14/04/20	20/04/20	-	-	-	-	None
Cardiovascular Disease	31/05/20	01/06/20	NS	No	No	No	National Natural Science Foundation of China
Children	15/04/20	21/04/20	-	-	-	-	None
Children	18/04/20	20/04/20	-	-	-	-	Nanchang University

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Children	02/08/20	06/08/20	RN*	No	-	Potentially. Four months since previous systematic review	None
Comorbidities: Impact on Mortality	24/03/20	03/04/20	-	-	-	-	None
Comorbidities: Impact on Mortality	22/05/20	28/05/20		No	None	No	None
Comorbidities: Impact on Mortality	29/10/20	30/10/20	NS*	No	None	Perhaps- to update evidence (5 months after last review).	None
Comorbidities: Prevalence	27/03/20	06/04/20	-	-	-	-	Human Resources Development Operational Programme Grant
Comorbidities: Prevalence	26/04/20	28/04/20	NS*	No	No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Comorbidities: Severe Outcomes and Death	26/02/20	17/03/20	-	-	-	-	National Key R&D Program of China.
Comorbidities: Severe Outcomes and Death	26/03/20	16/04/20	SD	Yes	Yes: no risk of bias in CRD42020170315	Yes, CRD42020170315 do not report methods of quality assessment).	None
Comorbidities: Severe Outcomes and Death	31/03/20	30/04/20	NS	No	None	No	None
Comorbidities: Severe Outcomes and Death	13/04/20	16/04/20	NS	No	None	No	Second Affiliated Hospital of Nanchang University
COVID-19 in Healthcare Workers	06/04/20	15/04/20	--	-	-	-	None
COVID-19 in Healthcare Workers	27/04/20	28/04/20	NS	None	No	No	None
Diabetes	28/04/20	04/05/20	-	-	-	-	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Diabetes	30/06/20	30/06/20	NS	No	None	No	Natural Science Foundation of Tianjan and Tianjan Education Committee
Diabetes	05/10/20	06/10/20	NS	No	None	Perhaps update of review potentially needed	None
Echocardiographic Findings	18/08/20	19/08/20	-	-	-	-	None
Echocardiographic Findings	19/09/20	22/09/20	NS	No	No	No	None
Face Masks	29/09/20	29/09/20	-	-	-	-	None
Face Masks	19/10/20	28/10/20	SD	No	No	Yes. Living systematic review	None
General Risk Factors: Impact on Mortality	26/03/20	03/04/20	-	-	-	-	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
General Risk Factors: Impact on Mortality	04/04/20	09/04/20	NS	None	No	Potentially- only one day after previous record was registered.	Wellcome Trust
General Risk Factors: Impact on Poor Outcomes and Mortality	27/02/20	03/04/20	-	-	-	-	National Natural Science Foundation
General Risk Factors: Impact on Poor Outcomes and Mortality	15/03/20	27/03/20	-	-	-	-	None
General Risk Factors: Impact on Poor Outcomes and Mortality	18/03/20	23/03/20	NS	None	No	No	Chinese Natural Science Foundation and the Training Program of Shanghai Health and Family Planning System
General Risk Factors: Impact on Poor Outcomes and Mortality	28/03/20	09/04/20	SD	Yes	Yes, provide additional analysis (regression)	Yes	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
General Risk Factors: Impact on Poor Outcomes and Mortality	12/04/20	16/04/20	NS	No	None	No	None
General Risk Factors: Impact on Poor Outcomes and Mortality	14/04/20	17/05/20	NS*	No	None	None	None
General Risk Factors: Impact on Poor Outcomes and Mortality	20/04/20	21/04/20	RN	No	None	None	None
General Risk Factors: Impact on Poor Outcomes and Mortality	06/05/20	06/05/20	SD	No	None	No	Department of Epidemiology, College of Public Health, University of Nebraska Medical
General Risk Factors: Impact on Poor Outcomes and Mortality	11/05/20	12/05/20	NS	No	None	No	None
Long COVID	15/10/20	23/10/20	-	-	-	-	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Long COVID	31/10/20	02/11/20	SD	No	No	No	None
Manifestations: Taste and Smell	22/05/20	29/05/20	-	-	-	-	None
Manifestations: Taste and Smell	20/06/20	25/06/20	NS	No	None	None	Health Commission of Hunan Province and Human Pharmaceutical Association
Mental Health in Healthcare Workers	31/07/20	03/08/20	-	-	-	-	National Council for Scientific and Technological Development - CNPq, Brazilian Government
Mental Health in Healthcare Workers	19/10/20	22/10/20	NULL	No	No	No	None
Neurological Manifestations	22/05/20	01/06/20	-	-	-	-	None
Neurological Manifestations	02/06/20	02/06/20	NS	No	None	Perhaps, submitted one day after previous was published	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Obesity	13/04/20	06/04/20	-	-	-	-	NIHR Applied Research and Care
Obesity	29/04/20	01/05/20	NS	None	None	No	University of Indonesia
Obesity	13/05/20	15/05/20	NS	No	None	None	Programme Széchenyi 20
Obesity	10/11/20	12/11/20	SD	No	No	Perhaps update of review potentially needed	None
Pregnancy	04/04/20	23/06/20	-	-	-	-	Partly funded by WHO
Pregnancy	13/04/20	17/04/20	-	-	-	-	None
Pregnancy	24/04/20	24/04/20	NS*	No	None	No	None
Skin Manifestations	23/06/20	25/06/20	-	-	-	-	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Skin Manifestations	28/06/20	29/06/20	SD	Yes	Yes (none will be published before completion)	No	None
Treatment: ACE Inhibitors and ARBs	07/06/20	19/06/20	-	-	-	-	Major Project of National Science and Technology on New Drug etc.
Treatment: ACE Inhibitors and ARBs	03/07/20	08/07/20	SD	No	None	No	None
Treatment: Metformin	21/08/20	25/08/20	-	-	-	-	ARC-EM
Treatment: Metformin	12/09/20	15/09/20	RN	None	None	No	National Natural Science China
Breastfeeding	06/04/20	21/04/20	SD	References CRD420173886	Yes. But review is sufficiently so no duplication occurred.	Yes	None
Breastfeeding	11/04/20	20/04/20	N/A	-	-	-	None
Breastfeeding	17/07/20	20/07/20	SD	Not explicitly	No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Breastfeeding		10/10/20	NS	No	No	No comparator.	None
Maternal to Fetal Transmission	16/03/20	24/03/20	NS	-	-	-	N/A
Maternal to Fetal Transmission	22/06/20	03/07/20	SD	No	No	No	None
Surgery	02/04/20	22/04/20	NS	-	-	-	None
Surgery	25/04/20	28/04/20	NS	No	N/A	No	None
Viral Shedding	24/04/20	29/04/20	NS	-	-	-	None
Viral Shedding	22/06/20	22/06/20	NS*	Yes, acknowledge CRD420181914	Yes, previous registration deemed poor quality	Potentially- poor reporting in previous registration. Authors have given reason for duplication.	None
Weather	28/03/20	07/04/20	NS	-	-	-	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Weather	01/04/20	08/04/20	NS	-	-	-	Federal University of Pará, Brazil.
Weather	27/04/20	30/04/20	NS	No	No	Yes, looking at seasons and times of year rather than climate conditions.	None
Weather	03/07/20	03/07/20	SD	No	No	Almost identical. No real reason for duplication.	None
Ace inhibitors	05/04/20	14/04/20	NS	-	-	-	Self funded
Ace inhibitors	13/04/20	17/04/20	NS*	-	-	-	None
Ace inhibitors	03/05/20	05/05/20	NS	No	NO	NO	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Ace inhibitors	04-Mayx-20	04/05/20	NS	No	NO	NO	China Postdoctoral Science Foundation (2019M652593) and Henan Postdoctoral Science Foundation (1902006)
Ace inhibitors	08/05/20	11/05/20	SD	Partially	NO	NO	None
Ace inhibitors	13/05/20	14/05/20	NS	No	NO	NO	This study was supported by National Natural Science Foundation of China, 81970203; National Natural Science Foundation of China, 81570212; National Natural Science Foundation of China, 31800976 Chongqing Science and Health Joint Medical Research Project, 2018QNXM024
Ace inhibitors	27/07/20	28/07/20	NS	No	NO	NO	Qingsong Qin is sponsored by Department of education of Guangdong province, China

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Ace inhibitors	03/08/20	04/08/20	SD	Partially	NO	NO	Disciplines Construction Project of PUMC (Grant number: 20192102). Chinese Academy of Medical Sciences, CAMS Innovation Fund for Medical Sciences (Grant number: 2018-I2M-1-002)
All treatment living	20/04/20	22/04/20	SD	-	-	-	None
All treatment living	27/04/20	28/04/20	SD	Partially	NO	No	This review received some funding from the Agence Nationale de la Recherche (ANR) and from the WHO
All treatment MA	07-Feb-20	31/03/20	NS	-	-	-	NA

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
All treatment MA	09/03/20	20/03/20	NS	No	No	No	This study will be funded by Research Funds of Shanghai Health and Family Planning commission (20184Y0022, 20194Y0007), Cultivation fund of clinical research of Renji hospital (PY2018-III-06), Clinical Pharmacy Innovation Research Institute of Shanghai Jiao Tong University School of Medicine (CXYJY2019ZD001, CXYJY2019QN004).
All treatment MA	22/03/20	24/03/20	NS	No	No	No	Shubham Misra is a recipient of DST-INSPIRE PhD Fellowship from Department of Science & Technology, Government of India
All treatment MA	07/04/20	17/04/20	NS	No	No	No	https://covid19.kacst.edu.sa/grants/

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
All treatment MA	20/04/20	22/04/20	SD	Partially	No	No	None
All treatment MA	05/05/20	06/05/20	NS	No	No	No	None
All treatment MA	13/10/20	16/10/20	NS	No	No	No	This work was funded by the Guidance Plan for Social Development of Taizhou Municipal Science and Technology (ssf20160141).
All treatment MA	14/11/20	07/12/20	NS	No	No	No	None
All treatment MA	05/01/21	08/01/21	Not in system	No	No	No	None
All treatment NMA	07/04/20	15/04/20	NS	NO	Yes		
All treatment NMA	12/04/20	16/04/20	SD	Partially	NA		
All treatment NMA	18/04/20	22/04/20	SD	Partially	No	No	The research project will be assisted with the by Griffith University

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
							Postgraduate Research Scholarship
All treatment NMA	19/04/20	20/04/20	NS	NO	No	No	None
All treatment NMA	23/04/20	23/04/20	NS	NO	No	No	Supported by the Programme of Introducing Talents of Discipline to Universities, China, the 111 Project, D18011)
All treatment NMA	27/04/20	27/04/20	SD	Partially	No	No	None
All treatment NMA	15/05/20	19/05/20	NS	NO	No	No	None
All treatment NMA	18/06/20	24/06/20	NS	NO	No	No	None
All treatment NMA	18/10/20	26/10/20	NS	NO	No	No	None
All treatment umbrella	13/05/20	20/05/20	NS	NA	NA	NA	NA

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
All treatment umbrella	07/09/20	07/09/20	NS	No	No	No	Indian Council of Medical Research
All treatment umbrella	04/10/20	05/10/20	NS	No	No	No	None
Anticoagulant	02/06/20	02/06/20	NS	-	-	-	
Anticoagulant	02/07/20	03/07/20	SD	Partially	No	No	None
Anticoagulant	14/10/20	15/10/20	NS	No	No	No	None
Anticoagulant	07/01/21	11/01/21	not in list	No	No	No	None
Blood plasma	12/03/20	24/03/20	NS	-	-	-	None
Blood plasma	28/03/20	08/04/20	SD	Partially		No reasons why sufficiently different.	Funded by the UK Forum
Blood plasma	02/04/20	02/04/20	NS	No	No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Blood plasma	06/04/20	15/04/20	SD	Partially	No	No reasons why sufficiently different.	None
Blood plasma	10/04/20	15/04/20	NS	No	No	No	Education Foundation of Chengdu University of Traditional Chinese Medic
Blood plasma	17/06/20	19/06/20	SD	Partially	No	No	None
Blood plasma	05/07/20	06/07/20	SD	Partially	No	No reasons why sufficently different.	None
Blood plasma	16/07/20	16/07/20	NS	No	No	No	None
Blood plasma	12/08/20	14/08/20	SD	Partially	No	No reasons why sufficently different.	None
Blood plasma	09/12/20	22/12/20	not in list	No	No	No	None
Blood plasma	16/12/20	17/12/20	not in list		No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Blood plasma	21/12/20	22/12/20	not in list	No	Potentially severe patient pop.	No	None
Colchicine	17/09/20	21/09/20					None
Colchicine	11/01/21	12/01/21	not in list	No	No	No	None
Corticosteroids	03/03/20	20/04/20	NS	-	-	-	None
Corticosteroids	20/04/20	21/04/20	NS	-	-	-	None
Corticosteroids	28/04/20	30/04/20	NS	No	No	No	None
Corticosteroids	06/05/20	06/05/20	SD	Partially	No	No	This work was supported by National Key Research and Development Project (20YFC2005700), Key Realm R&D Program of Guangdong Province (2019B030335001), and Medical Scientific Research

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
							Foundation of Guangdong Province of China (A2019407)
Corticosteroids	07/07/20	07/07/20	SD	Partially	No	No	None
Corticosteroids	23/09/20	23/09/20	SD	Partially	No	No	None
Corticosteroids	07/12/20	08/12/20	not in list	No	No	No	None
Corticosteroids	21/12/20	22/12/20	not in list	No	No	No	NaFoUniMedCovid19" (FKZ: 01KX21) „CEO-Sys“
Corticosteroids	05/01/21	12/01/21	not in list	No	No	No	None
ECMO	02/04/20	14/04/20		-	-	-	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
ECMO	07/04/20	14/04/20		-	-	-	None
ECMO	16/04/20	17/04/20	NS	No	No	No	None
ECMO	03/05/20	04/05/20	SD	Partially	No	No	None
ECMO	15/06/20	18/06/20	NS	No	No	No	None
ECMO	19/06/20	22/06/20	NS	No	No	No	None
ECMO	17/09/20	21/09/20	NS	No	No	No	None
ECMO	22/11/20	23/11/20	NS	No	No	No	This work was supported by the research Grant 20YFC0841300 from Ministry of Science and Technology of the People's Republic of China.
ECMO	21/12/20	22/12/20	NS	No	No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
ECMO	04/01/21	07/01/21	NS	No	No	No	None
Hydroxychloroquine	22-Feb-20	17/03/20		-	-	-	None
Hydroxychloroquine	29/03/20	16/04/20	NS	No	No	No	Major Projects of Science and Technology Innovation 2025 in Ningbo, China
Hydroxychloroquine	04/04/20	06/04/20	SD	Partially	No	No	NIHR Applied Research Collaboration East Midlands (ARC EM), UK
Hydroxychloroquine	06/04/20	07/04/20	SD	Partially	No	No	None
Hydroxychloroquine	06/04/20	09/04/20	NS	No	No	No	None
Hydroxychloroquine	07/04/20	17/04/20	NS	No	No	No	None
Hydroxychloroquine	10/04/20	21/04/20	SD	Partially	No	No	None
Hydroxychloroquine	14/04/20	17/04/20	SD	Partially	No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Hydroxychloroquine	20/04/20	21/04/20	SD	Partially	No	No	None
Hydroxychloroquine	27/04/20	28/04/20	NS	No	No	No	None
Hydroxychloroquine	22/05/20	22/05/20	SD	Partially	No	No	None
Hydroxychloroquine	10/08/20	12/08/20	NS	No	No	No	None
Hydroxychloroquine	19/08/20	19/08/20	NS	No	No	No	None
Hydroxychloroquine	12/09/20	17/09/20	NS	No	No	No	None
Hydroxychloroquine	12/09/20	15/09/20	SD	Partially	No	No	None
Interferon	26/03/20	26/03/20	NA	-	-	-	None
Interferon		07/04/20	NA	-	-	-	None
Interferon	17/11/20	20/11/20	SD	Partially	No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Interferon	21/11/20	03/12/20	NS	No	No	No	None
Ivermectin	08/07/20	09/07/20		-	-	-	-
Ivermectin	20/10/20	09/11/20	NS	no	No	No	None
Ivermectin	24/12/20	07/01/21	NS	no	No	No	The Institute for Health Technology Assessment (IETS),
Ivermectin	11/01/21	12/01/21	NS	no	No	No	None
JAK inhibitors	07/06/20	09/06/20		-	-	-	NA
JAK inhibitors	04/01/21	12/01/21	SD	partially	no	no	None
lopinavir	06/04/20	15/04/20	NA	NA	NA	NA	NA
lopinavir	09/04/20	15/04/20	NA	NA	NA	NA	NA

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
lopinavir	12/04/20	16/04/20	NA	NA	NA	NA	NA
lopinavir	17/04/20	21/04/20	NS	no	no	no	None
lopinavir	24/04/20	24/04/20	NS	no	no	no	None
lopinavir	13/01/21	15/01/21	SD	partially	no	no	This study is carried out at the request of the Ministry of Health and Social Protection and the Disaster Risk Management Fund. Contract No. 9677-MECOV19-1009-20.
Prone position	24/06/20	24/06/20	NA	-	-	-	-
Prone position	28/08/20	01/09/20	NS	no	no	no	None
Prone position	11/09/20	14/09/20	NS	no	no	no	None
Prone position	19/10/20	22/10/20	NS	no	no	no	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Prone position	16/11/20	20/11/20	RN	yes	no	no	None
Prone position	10/12/20	11/12/20	NS	no	no	no	None
Prone position	12/12/20	14/12/20	NS	no	no	no	None
RAAS	07/05/20	11/05/20		-	-	-	None
RAAS	14/06/20	17/06/20	NS	no	no	no	None
RAAS	15/09/20	16/09/20	RN	yes	no	no	None
Remdisivir	08-Feb-20	23/03/20	NS	-	-	-	National Natural Science Foundation of China
Remdisivir	02/04/20	14/04/20	NS	No	No	No	CDT-Africa, College of Health Sciences, Addis Ababa University
Remdisivir	21/04/20	23/04/20	NS	No	No	No	None
Remdisivir	30/04/20	01/05/20	SD	No	No	No	None

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
Remdisivir	26/05/20	26/05/20	NS	No	No	No	Tongji Hospital, Tongji Medical College
Remdisivir	20/09/20	21/09/20	NS	No	No	No	None
Remdisivir	12/10/20	15/10/20	NS	No	No	No	Zhejiang Medicine and Health Science and Technology Project; Natural Science Foundation of Zhejiang Province
Tocilizumab	22/03/20	24/03/20	NS	-	-	-	None
Tocilizumab	18/06/20	19/06/20	NS		No	No	None
Tocilizumab	21/06/20	22/06/20	SD		No	No	None
Tocilizumab	26/06/20	01/07/20	NS		No	No	Nicola Luigi Bragazzi and Jianhong Wu are partially supported by the Canadian Institute of Health Research

Research area	Date submitted	Date registered	Answer to screening question?	Have authors acknowledged similar reviews?	Authors reason for duplication?	Is there reason for duplication from our perspective?	Is the review funded?
							(CIHR) 2019 Novel Coronavirus (COVID-19) rapid research program
Tocilizumab	14/08/20	17/08/20	NS		No	No	None
Tocilizumab	06/11/20	10/11/20	NS	no	No	No	None
Tocilizumab	11/12/20	18/12/20	NS	no	No	No	1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
Tocilizumab	16/12/20	17/12/20	SD	Partially	No	No	None
<p>* Registrant changed their answer to the screening question. Grey cells represent 'duplicate' records, white cells represent records registered first. Abbreviations: NS, Not Similar; RN, Repetition Needed; SD, Sufficiently Different.</p>							

Appendix E

Duplicate Registrations Characteristics

Table 2: Number of 'duplicate' records registered in each COVID-19 related topic area.

Topic	N duplicates
Epidemiology	
Health Condition and Impact on Outcome	
Cancer	1
Cardiovascular disease	1
Diabetes	2
General Risk Factors	8
Obesity	3
Comorbidities	6
Healthcare Workers	
COVID-19 in healthcare workers	1
Mental Health in Healthcare Workers	1
Clinical presentation of COVID-19	
Echocardiographic Findings	1
Manifestations (Dermatological)	1
Manifestations (Taste and Smell)	1
Manifestations (Neurological)	1
Long-COVID	1
Transmission of COVID-19	
Facemasks	1
Pregnancy and mother-baby transmission	1
Treatment of COVID-19	
ACE-inhibitors	1
Metformin	1
Total number of duplicates	31
Treatments	
All treatments	
All treatment living	1
All treatment MA	7
All treatment umbrella	2
All treatment NMA	8
Pharmacological interventions	
ACE-inhibitors	6
Anticoagulants	1
Corticosteroids	4
Hydroxychloroquine	14
Interferon	2

Ivermectin	3
JAK inhibitors	1
Topic	N duplicates
Pharmacological interventions	
lopinavir	3
RAAS	2
Remdisivir	6
Tocilizumab	7
Non-pharmacological interventions	
Blood plasma	8
ECMO	5
Prone position	6
Total number of duplicates	86
Transmission	
Mother-baby transmission	2
Transmission during Surgery	1
Weather	1
Total number of duplicates	4

